FDAmanufacturing / CMC54% confidence
Other | Cancer Accelerated Approvals
Source: FDA
Why This Matters
Why this matters: provides agency context on manufacturing / CMC that may shape timing or evidence expectations for Teva.
Regulatory Analysis
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been granted for supportive care products and changes to dosing or formulation.
Supporting Context
- Therapeutic area
- Hematology · Thrombocytopenia
- Sub-indication
- General
Related signal: Teva's Eltrombopag Olamine ANDA209938 Receives Approval